However, CD22-targeting antibodies like Epratuzumab have been tested in clinical trials [NCT0030182, NCT01262365, NCT01261793], which proved to be safe and well-tolerated in lymphoma as well as lupus patients. This evidence concerns the gene CD22 and systemic lupus erythematosus.